Results 51 to 60 of about 841 (115)

Deacetylase inhibitors CM‐444 and CM‐1758 enhance chemotherapy response in AML via ALOX5

British Journal of Haematology, EarlyView.
Naroa Gimenez‐Camino, Edurne San José‐Enériz, Leire Garate, Estibaliz Miranda, Elena Sáez, Antonio Pineda‐Lucena, Felipe Prósper, Xabier Agirre   +7 more
wiley   +1 more source

Nanomedicine Targeting Macrophage Immunometabolism in Atherosclerosis: Mechanisms and Therapeutic Prospects

Organ Medicine, Volume 3, Issue 1, Page 27-53, March 2026.
ABSTRACT Atherosclerosis, a chronic inflammatory–metabolic disorder, remains a leading cause of cardiovascular morbidity worldwide. This review explores the emerging paradigm of nanomedicine‐based targeting of macrophage immunometabolic reprogramming as a potentially transformative strategy for atherosclerosis treatment.
Zhenyu Liu, Wenfan Yang, Na Wang, Ya Wu
wiley   +1 more source

Light‐Activated Multifunctional Nanoplatforms: Reshaping Combination Therapy to Overcome Multidrug Resistance in Breast Cancer

Small Structures, Volume 7, Issue 3, March 2026.
Multidrug resistance in breast cancer constitutes a major therapeutic obstacle. This review examines light‐activated nanoplatforms combining photothermal and photodynamic therapies to overcome this challenge. Through rational design, these systems enable spatiotemporal control, enhanced tumor targeting, and synergistic antitumor efficacy.
Xianghui Duan, Gangcui Li, Hong Wang, Yanan Zhou, Hai Du, Qin Sun, Fulan Zhao, Luyin Yang, Pan Liang, Wei Ren   +9 more
wiley   +1 more source

A Facile Protocol for C(sp2)–C(sp3) Bond Formation Reactions Toward Functionalized E3 Ligase Ligands

ChemMedChem, Volume 21, Issue 4, 25 February 2026.
A robust C(sp2)–C(sp3) decarboxylative coupling strategy enables access to new CRBN ligands and degraders with improved physicochemical properties. This synthetic approach is expanding the chemical space beyond C(sp2)–N linkages, fine‐tuning proteolysis‐targeting chimera activities and unlocking previously inaccessible degrader chemotypes.
Anita Maksutova, Thomas M. Geiger, Lorenzo Cianni, Dominika E. Pieńkowska, Jan Gerhartz, Lina Read, Aleša Bricelj, Alexander Herrmann, Maurice Leon Nelles, Yuen Lam Dora Ng, Marcus D. Hartmann, Jan Krönke, Izidor Sosič, Radosław P. Nowak, Michael Gütschow, Christian Steinebach   +15 more
wiley   +1 more source

Cell‐Free DNA‐Based Theranostics for Inflammatory Disorders

Advanced Science, Volume 13, Issue 12, 27 February 2026.
Summary on the dual potential of cfDNA as biomarkers and therapeutic targets for inflammatory disorders. Figure was created with BioRender.com. ABSTRACT Inflammatory disorders are characterized by immune‐mediated inflammatory cascades that can affect multiple organs.
Jiatong Li, Yumei Wang, Xiaoxi Fan, Miao Xu, Jiawen Li, Wenfei Tan, Jianxiang Zhang, Heran Li   +7 more
wiley   +1 more source

Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation. [PDF]

Bioconjug Chem
Lu X, Hu Q.
europepmc   +1 more source

Editorial: Next-generation PROTACs in oncology and beyond: exploring therapeutic targets and their degraders. [PDF]

Front Pharmacol
Liao D, Bandyopadhyay D.
europepmc   +1 more source

Evolution of proteolysis-targeting chimeras (PROTAC) technology to overcome challenges of antimicrobial resistance. [PDF]

NPJ Antimicrob Resist
Sarwan DN, Khedekar PB, Bhole RP, Chikhale RV.   +3 more
europepmc   +1 more source

Nanotechnology Advances Proteolysis Targeting Chimeras (PROTACs): Transition From Basic Research to Clinical Application. [PDF]

Int J Nanomedicine
Mu X, Mu C, Wang M, Meng C, Liu H, Lu H.
europepmc   +1 more source

Rational design of the linkers in targeting chimeras. [PDF]

Chem Sci
Duan Y, Cai MY, Xu J, Hu Q.
europepmc   +1 more source